127 related articles for article (PubMed ID: 31796975)
1. When to Worry about Cancer: Concurrent Carcinoma and Recurrence in Borderline Ovarian Tumors.
Sullivan MW; Modesitt SC
South Med J; 2019 Dec; 112(12):634-638. PubMed ID: 31796975
[TBL] [Abstract][Full Text] [Related]
2. A nationwide study of ovarian serous borderline tumors in Denmark 1978-2002. Risk of recurrence, and development of ovarian serous carcinoma.
Hannibal CG; Vang R; Junge J; Frederiksen K; Kurman RJ; Kjaer SK
Gynecol Oncol; 2017 Jan; 144(1):174-180. PubMed ID: 27836204
[TBL] [Abstract][Full Text] [Related]
3. [Clinicopathologic analysis of 130 cases of mucinous borderline ovarian tumors].
Cao DY; Shen K; Tao T; Yang JX; Xiang Y; Huang HF; Wu M; Pan LY; Lang JH
Zhonghua Fu Chan Ke Za Zhi; 2011 Jan; 46(1):15-8. PubMed ID: 21429428
[TBL] [Abstract][Full Text] [Related]
4. Clinical value of human epididymis protein 4 and the Risk of Ovarian Malignancy Algorithm in differentiating borderline pelvic tumors from epithelial ovarian cancer in early stages.
Kotowicz B; Fuksiewicz M; Sobiczewski P; Spiewankiewicz B; Jonska-Gmyrek J; Skrzypczak M; Kowalska M
Eur J Obstet Gynecol Reprod Biol; 2015 Nov; 194():141-6. PubMed ID: 26398337
[TBL] [Abstract][Full Text] [Related]
5. Serous and mucinous borderline ovarian tumours: differences in clinical presentation, high-risk histopathological features, and lethal recurrence rates.
Vasconcelos I; Darb-Esfahani S; Sehouli J
BJOG; 2016 Mar; 123(4):498-508. PubMed ID: 26705090
[TBL] [Abstract][Full Text] [Related]
6. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors.
Engelen MJ; de Bruijn HW; Hollema H; ten Hoor KA; Willemse PH; Aalders JG; van der Zee AG
Gynecol Oncol; 2000 Jul; 78(1):16-20. PubMed ID: 10873403
[TBL] [Abstract][Full Text] [Related]
7. Retrospective evaluation of borderline ovarian tumors: single center experience of 183 cases.
Gungor T; Cetinkaya N; Yalcin H; Ozdal B; Ozgu E; Baser E; Uygur D; Caglar M; Sirvan L; Erkaya S
Arch Gynecol Obstet; 2015 Jan; 291(1):123-30. PubMed ID: 25047273
[TBL] [Abstract][Full Text] [Related]
8. Conservative treatment of borderline ovarian tumors: the experience of one clinical center.
Olszewska H; Abacjew-Chmylko A; Sawicki S; Olszewski J; Wydra DG
Ginekol Pol; 2015 Sep; 86(9):653-8. PubMed ID: 26665565
[TBL] [Abstract][Full Text] [Related]
9. Conservative surgery in ovarian borderline tumours: a meta-analysis with emphasis on recurrence risk.
Vasconcelos I; de Sousa Mendes M
Eur J Cancer; 2015 Mar; 51(5):620-31. PubMed ID: 25661104
[TBL] [Abstract][Full Text] [Related]
10. Pathologic findings in eight cases of ovarian serous borderline tumors, three with foci of serous carcinoma, that preceded death or morbidity from invasive carcinoma.
Lee KR; Castrillon DH; Nucci MR
Int J Gynecol Pathol; 2001 Oct; 20(4):329-34. PubMed ID: 11603215
[TBL] [Abstract][Full Text] [Related]
11. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
Silva EG; Gershenson DM; Malpica A; Deavers M
Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
[TBL] [Abstract][Full Text] [Related]
12. Mucinous tumors of the ovary: a clinicopathologic study of 196 borderline tumors (of intestinal type) and carcinomas, including an evaluation of 11 cases with 'pseudomyxoma peritonei'.
Lee KR; Scully RE
Am J Surg Pathol; 2000 Nov; 24(11):1447-64. PubMed ID: 11075847
[TBL] [Abstract][Full Text] [Related]
13. Ovarian epithelial tumors of borderline malignancy. A clinical and pathologic study of 109 cases.
Bostwick DG; Tazelaar HD; Ballon SC; Hendrickson MR; Kempson RL
Cancer; 1986 Nov; 58(9):2052-65. PubMed ID: 3756820
[TBL] [Abstract][Full Text] [Related]
14. Ovarian serous borderline tumors with invasive peritoneal implants.
Gershenson DM; Silva EG; Levy L; Burke TW; Wolf JK; Tornos C
Cancer; 1998 Mar; 82(6):1096-103. PubMed ID: 9506355
[TBL] [Abstract][Full Text] [Related]
15. Ultrasound, physical examination, and CA 125 measurement for the detection of recurrence after conservative surgery for early borderline ovarian tumors.
Zanetta G; Rota S; Lissoni A; Meni A; Brancatelli G; Buda A
Gynecol Oncol; 2001 Apr; 81(1):63-6. PubMed ID: 11277651
[TBL] [Abstract][Full Text] [Related]
16. Ovarian intestinal type mucinous borderline tumors: are we ready for a nomenclature change?
Chiesa AG; Deavers MT; Veras E; Silva EG; Gershenson D; Malpica A
Int J Gynecol Pathol; 2010 Mar; 29(2):108-12. PubMed ID: 20173495
[TBL] [Abstract][Full Text] [Related]
17. Mucinous tumors of the ovary: a clinicopathologic analysis of 75 borderline tumors (of intestinal type) and carcinomas.
Rodríguez IM; Prat J
Am J Surg Pathol; 2002 Feb; 26(2):139-52. PubMed ID: 11812936
[TBL] [Abstract][Full Text] [Related]
18. A retrospective analysis of borderline ovarian tumors in a Greek university hospital.
Liapis A; Bakalianou K; Iavazzo C; Salakos N; Paltoglou G; Kondi-Pafiti A
Eur J Gynaecol Oncol; 2008; 29(4):383-5. PubMed ID: 18714575
[TBL] [Abstract][Full Text] [Related]
19. Borderline and invasive epithelial ovarian tumors in young women.
Carter J; Fowler J; Carlson J; Carson L; Twiggs LB
Obstet Gynecol; 1993 Nov; 82(5):752-6. PubMed ID: 8414321
[TBL] [Abstract][Full Text] [Related]
20. Fertility-sparing surgery for young patients with borderline ovarian tumors (BOTs): single institution experience.
Chen RF; Li J; Zhu TT; Yu HL; Lu X
J Ovarian Res; 2016 Mar; 9():16. PubMed ID: 26988551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
